IN8bio (INAB) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 42.5% versus a loss of 89.6%. Over five years, INAB leads with a -99.3% price change compared with -99.3% for KPTI. Karyopharm Therapeutics is the larger company by market cap ($13.7 million vs $13.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | KPTI |
|---|---|---|
| Share price | $1.34 | $0.605 |
| Market cap | $13.21M | $13.72M |
| 1-day change | -2.90% | +0.83% |
| YTD return | -42.74% | -91.78% |
| 1-year return | -42.49% | -89.60% |
| 5-year return | -99.26% | -99.28% |
| EPS (TTM) | $-1.62 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $10.99 |
| 52-week low | $0.88 | $0.5652 |
| Distance from 52-week high | -50.92% | -94.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +422.39% | +1098.35% |
| Average volume | 57.49K | 1.71M |
| Shares outstanding | 9.86M | 22.68M |
| Employees | 18 | 228 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed KPTI by 47.1 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
INAB vs KPTI FAQ
Which is bigger, IN8bio or Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) is larger, with a market capitalization of $13.72M compared with $13.21M for IN8bio (INAB).
Which stock has performed better over the past year, INAB or KPTI?
INAB returned -42.49% over the past 12 months, compared with -89.60% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Karyopharm Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for IN8bio and Biotechnology: Pharmaceutical Preparations for Karyopharm Therapeutics.